Companies › Omeros
2 active drug programs in 3 registered trials: 3 Phase 2; Hematology, Genitourinary; next expected readout Dec 2026.
Open in Phaseline: competitors, likelihood bands and readouts Company report
| Drug | Target | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|
| OMS906 | – | Phase 2 | C3 Glomerulopathy; Paroxysmal Nocturnal Hemoglobinuria | Dec 2026 |
| narsoplimab Mannan-binding lectin serine protease 2 inhibitor | MASP2 | Phase 2 | Thrombotic Microangiopathies | – |
| Registry id | Drug | Phase | Conditions | Area | Expected readout |
|---|---|---|---|---|---|
| NCT05855083 | narsoplimab | Phase 2 | Thrombotic Microangiopathies | Hematology | Dec 2025 |
| NCT06209736 | OMS906 | Phase 2 | C3 Glomerulopathy | Genitourinary | Apr 2026 |
| NCT06298955 | OMS906 | Phase 2 | Paroxysmal Nocturnal Hemoglobinuria | Hematology | Dec 2026 |
Cash and short-term investments of $132m on 2026-06-30; operating cash outflow about $21m a year; runway about 75 months at that burn, to Oct 2032; 1 of 1 coming phase 2-3 readouts fall inside that runway
Press releases filed as 8-K in the last year:
–
Climb Bio Shanghai RAAS Blood Products S-INFINITY Pharmaceuticals Prothya Biosolutions Imara
Pipelines of the same shape: areas, drug types, target families, stage and cash runway.
Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.